Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Iveric sees a path forward in geographic atrophy
But data from Gather2 do not look as impressive as earlier results.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
No land grab for Gemini in geographic atrophy
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Allergan’s eye contender cannot knock Eylea off its perch
Allergan's wet AMD candidate abicipar has apparently succeeded in phase III – but a safety signal could make it hard to compete against Regeneron's Eylea.
